BMS-299897 has been used as an γ-secretase inhibitor to stop high glucose (HG) mediated amyloid β-peptide (Aβ) secretion.[1]
Biochem/physiol Actions
BMS-299897 is a gamma-secretase inhibitor
BMS-299897 is a potent inhibitor of γ-secretase. The comound is 15-fold more selective for inhibiting the cleavage of β-amyloid precursor protein over Notch cleavage (IC50s 7.1 and 105.9, respectively). In vivo, BMS-299897 blocks the formation of Aβ40 and Aβ42 in the brain and CSF without affecting maturation of CD8+ T cells or intestinal goblet cells, suggesting Notch signalling was not significantly inhibited.
BMS-299897 may be used as a therapeutic for Alzheimer′s disease.[2]
Amyloid beta-peptide (Aβ), the main component of senile plaques in the Alzheimer's disease (AD) brains, is generated from sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretase. Hyperglycemia in diabetes may compromise barrier integrity in endothelial cells (ECs).
Current drug metabolism, 7(8), 883-896 (2006-12-16)
BMS-299897 is a gamma-secretase inhibitor that has the potential for treatment of Alzheimer's disease. The metabolism of [(14)C]BMS-299897 was investigated in human liver microsomes, in rat, dog, monkey and human hepatocytes and in bile duct cannulated rats. Seven metabolites (M1-M7)
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.